Entity
Yep
Eyepoint is a biopharmaceutical company that develops treatments for eye diseases, including a vision treatment called EYP-1001.
Why it’s in the news: It is in the news due to disappointing results from a clinical study for its vision treatment, though the company remains optimistic about the drug's potential.
Latest on Yep
- STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
- STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise
- Yep, we’re using OpenClaw to date now
Connections
1 entities linked to Yep across the news graph.
Also connected to (1)